CN113924116B - Her2抗体的组合 - Google Patents

Her2抗体的组合

Info

Publication number
CN113924116B
CN113924116B CN202080032056.9A CN202080032056A CN113924116B CN 113924116 B CN113924116 B CN 113924116B CN 202080032056 A CN202080032056 A CN 202080032056A CN 113924116 B CN113924116 B CN 113924116B
Authority
CN
China
Prior art keywords
seq
ser
gly
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080032056.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN113924116A (zh
Inventor
S·费舍尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAB Discovery GmbH
Original Assignee
MAB Discovery GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAB Discovery GmbH filed Critical MAB Discovery GmbH
Publication of CN113924116A publication Critical patent/CN113924116A/zh
Application granted granted Critical
Publication of CN113924116B publication Critical patent/CN113924116B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080032056.9A 2019-05-02 2020-04-29 Her2抗体的组合 Active CN113924116B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19172329.5 2019-05-02
EP19172329 2019-05-02
PCT/EP2020/061850 WO2020221791A1 (en) 2019-05-02 2020-04-29 Combination of her2 antibodies

Publications (2)

Publication Number Publication Date
CN113924116A CN113924116A (zh) 2022-01-11
CN113924116B true CN113924116B (zh) 2025-11-25

Family

ID=66625743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080032056.9A Active CN113924116B (zh) 2019-05-02 2020-04-29 Her2抗体的组合

Country Status (7)

Country Link
US (1) US20220204644A1 (enExample)
EP (1) EP3962525A1 (enExample)
JP (1) JP7660074B2 (enExample)
CN (1) CN113924116B (enExample)
AU (1) AU2020266253A1 (enExample)
CA (1) CA3137480A1 (enExample)
WO (1) WO2020221791A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4345113A1 (en) 2022-09-30 2024-04-03 SDS Optic Spolka Akcyjna Anti-her2 antibody, a nucleic acid molecule encoding the variable region of said antibody, a method of detecting her2 in a biological sample, an immuno-enzymatic elisa assay and use of said anti-her2 antibody or fragments therefof
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164160A (zh) * 2013-05-16 2015-12-16 艾克隆株式会社 特异性结合her2的抗体
CN109415443A (zh) * 2016-05-06 2019-03-01 Mab发现股份有限公司 Her-2结合抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009042618A1 (en) * 2007-09-24 2009-04-02 Tragara Pharmaceuticals, Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
BRPI0812682A2 (pt) * 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
CA2800769C (en) * 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
WO2016022723A1 (en) * 2014-08-05 2016-02-11 Merrimack Pharmaceuticals, Inc. Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapies
US20180271996A1 (en) * 2017-02-28 2018-09-27 Mersana Therapeutics, Inc. Combination therapies of her2-targeted antibody-drug conjugates
PT3589661T (pt) * 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105164160A (zh) * 2013-05-16 2015-12-16 艾克隆株式会社 特异性结合her2的抗体
CN109415443A (zh) * 2016-05-06 2019-03-01 Mab发现股份有限公司 Her-2结合抗体

Also Published As

Publication number Publication date
CA3137480A1 (en) 2020-11-05
US20220204644A1 (en) 2022-06-30
JP2022530272A (ja) 2022-06-28
CN113924116A (zh) 2022-01-11
EP3962525A1 (en) 2022-03-09
JP7660074B2 (ja) 2025-04-10
AU2020266253A1 (en) 2021-10-21
WO2020221791A1 (en) 2020-11-05

Similar Documents

Publication Publication Date Title
JP7530913B2 (ja) Ｃｄ７３遮断抗体
JP7754895B2 (ja) アゴニスト性ｃｄ４０抗体
JP6257646B2 (ja) 抗ｈｅｒ３抗体と抗ｈｅｒ２抗体の併用療法
JP7038462B2 (ja) ヒト化抗ｉｌ－１ｒ３抗体
US12129307B2 (en) HER-2 binding antibodies
JP2024026170A (ja) 癌を処置するための組成物及び方法
CN115461366B (zh) 抗ox40抗体及其用途
CN113924116B (zh) Her2抗体的组合
JP2026504816A (ja) 抗ｆｇｆｒ２ｂ抗体及びその用途
HK40029748A (en) Agonistic cd40 antibodies
HK40085822A (en) Anti-ox40 antibody and uses thereof
HK40085344A (en) Anti-ox40 antibody and uses thereof
HK40029748B (zh) 激动性cd40抗体
HK40003287A (en) Her-2 binding antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant